Pancreatic Adenocarcinoma, Version 2.2014
Margaret A. Tempero(Pancreatic Cancer Action Network), Mokenge P. Malafa(University of South Florida), Stephen W. Behrman(Pancreatic Cancer Action Network), Al B. Benson(Northwestern University), Ephraim S. Casper(Pancreatic Cancer Action Network), E. Gabriela Chiorean(Pancreatic Cancer Action Network), Vincent Chung(Pancreatic Cancer Action Network), Steven J. Cohen(Pancreatic Cancer Action Network), Brian G. Czito(Duke University), Anitra Engebretson(Pancreatic Cancer Action Network), Mary Feng(Pancreatic Cancer Action Network), William G. Hawkins(Pancreatic Cancer Action Network), Joseph M. Herman(Johns Hopkins University), John P. Hoffman(Fox Chase Cancer Center), Andrew H. Ko(Pancreatic Cancer Action Network), Srinadh Komanduri(Northwestern University), Albert C. Koong(Stanford University), Andrew M. Lowy(University of California, San Diego), Wen Wee(Roswell Park Comprehensive Cancer Center), Nipun B. Merchant(Pancreatic Cancer Action Network), Sean J. Mulvihill(University of Utah), Peter Muscarella(Pancreatic Cancer Action Network), Eric K. Nakakura(Pancreatic Cancer Action Network), Jorge Obando(Duke University), Martha B. Pitman(Pancreatic Cancer Action Network), Sushanth Reddy(University of Alabama at Birmingham), Aaron R. Sasson(Pancreatic Cancer Action Network), Sarah P. Thayer(Harvard University Press), Colin D. Weekes(University of Colorado Boulder), Robert A. Wolff(Pancreatic Cancer Action Network), Brian M. Wolpin(Pancreatic Cancer Action Network), Jennifer L. Burns(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 471
Abstract
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.
Related Papers
TNM Classification of Malignant Tumours
|Unknown|1987|16.1k